https://www.selleckchem.com/products/dup-697.html
9 [SD 15.6], 2.5 mg twice a day -10.6 [SD 7.7]), placebo -5.7 (SD 10.2); P less then .005 for both oxybutynin doses vs placebo), HF frequency (5 mg twice a day -7.5 [SD 6.6], 2.5 mg twice a day -4.8 [SD 3.2], placebo -2.6 [SD 4.3]; P less then .003 for both oxybutynin doses vs placebo), and improvement in most HF-related daily interference scale measures and in overall quality of life. Patients on both oxybutynin arms reported more side effects than patients on placebo, particularly dry mouth, difficulty urinating, and abdominal pai
Like
Comment
Share
